BR112019006735A2 - compostos e métodos para ativação da sinalização de tie2 - Google Patents
compostos e métodos para ativação da sinalização de tie2Info
- Publication number
- BR112019006735A2 BR112019006735A2 BR112019006735A BR112019006735A BR112019006735A2 BR 112019006735 A2 BR112019006735 A2 BR 112019006735A2 BR 112019006735 A BR112019006735 A BR 112019006735A BR 112019006735 A BR112019006735 A BR 112019006735A BR 112019006735 A2 BR112019006735 A2 BR 112019006735A2
- Authority
- BR
- Brazil
- Prior art keywords
- tie2
- methods
- activation
- compounds
- collagen
- Prior art date
Links
- 101100481408 Danio rerio tie2 gene Proteins 0.000 title abstract 4
- 230000004913 activation Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000008186 Collagen Human genes 0.000 abstract 2
- 108010035532 Collagen Proteins 0.000 abstract 2
- 230000003592 biomimetic effect Effects 0.000 abstract 2
- 229920001436 collagen Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 230000008728 vascular permeability Effects 0.000 abstract 2
- 102000009075 Angiopoietin-2 Human genes 0.000 abstract 1
- 108010048036 Angiopoietin-2 Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000001365 lymphatic vessel Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 210000005166 vasculature Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403786P | 2016-10-04 | 2016-10-04 | |
| PCT/US2017/055055 WO2018067646A1 (en) | 2016-10-04 | 2017-10-04 | Compounds and methods for activating tie2 signaling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019006735A2 true BR112019006735A2 (pt) | 2019-06-25 |
Family
ID=61832135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019006735A BR112019006735A2 (pt) | 2016-10-04 | 2017-10-04 | compostos e métodos para ativação da sinalização de tie2 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190225670A1 (enExample) |
| EP (1) | EP3522906B1 (enExample) |
| JP (1) | JP2019535651A (enExample) |
| KR (1) | KR20190066040A (enExample) |
| CN (1) | CN110177563A (enExample) |
| AU (1) | AU2017339970A1 (enExample) |
| BR (1) | BR112019006735A2 (enExample) |
| CA (1) | CA3038809A1 (enExample) |
| EA (1) | EA201990868A1 (enExample) |
| IL (1) | IL265694A (enExample) |
| MX (1) | MX2019003895A (enExample) |
| SG (1) | SG10202103032QA (enExample) |
| WO (1) | WO2018067646A1 (enExample) |
| ZA (1) | ZA201902344B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2643469T3 (es) | 2006-04-07 | 2017-11-23 | Aerpio Therapeutics, Inc. | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| AU2018266690A1 (en) * | 2017-05-08 | 2019-12-12 | Asclepix Therapeutics, Inc. | Biodegradable microparticles for sustained delivery of anti-angiogenic peptide |
| WO2019028427A1 (en) | 2017-08-03 | 2019-02-07 | Asclepix Therapeutics, Llc. | METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR |
| CN120058958A (zh) | 2018-09-24 | 2025-05-30 | 视点制药公司 | 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体 |
| JP7650074B2 (ja) * | 2019-03-26 | 2025-03-24 | アスクレピクス セラピューティクス インコーポレイテッド | 眼疾患を治療するための組成物及び方法 |
| CN117126233A (zh) * | 2022-05-20 | 2023-11-28 | 杭州禾泰健宇生物科技有限公司 | 一种类肽化合物及其应用 |
| WO2024044745A2 (en) * | 2022-08-26 | 2024-02-29 | Asclepix Therapeutics, Inc. | Formulations for intraocular delivery of peptides derived from type iv collagen |
| KR20240133892A (ko) * | 2023-02-28 | 2024-09-05 | 주식회사 파멥신 | 전신 모세혈관 누출 증후군의 예방 또는 치료용 조성물 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| ES2210306T3 (es) | 1994-07-20 | 2004-07-01 | The General Hospital Corporation | Sistemas de trampa para interacciones, para detectar interacciones de proteinas. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| DK2230303T3 (da) | 1999-05-05 | 2013-04-15 | Phylogica Ltd | Isolering af biologiske modulatorer fra biodiverse genfragment-biblioteker |
| EP1181358B1 (en) | 1999-05-26 | 2010-11-17 | Next Biomed Technologies NBT Oy | Methods and materials for generating sh3 domains with tailored binding properties |
| SE0001877D0 (sv) | 2000-05-22 | 2000-05-22 | Klaus Mosbach | Molecular imprinting |
| JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| DE10053224A1 (de) | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
| US20040132094A1 (en) | 2000-12-13 | 2004-07-08 | Michael Etzerodt | Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains |
| JP2005508623A (ja) | 2001-08-30 | 2005-04-07 | バイオレクシス ファーマシューティカル コーポレイション | 改変されたトランスフェリン融合タンパク質 |
| JP5376747B2 (ja) | 2002-10-02 | 2013-12-25 | カタリスト バイオサイエンシーズ， インコーポレイテッド | 改変された特異性を有するプロテアーゼを作製する方法およびスクリーニングする方法 |
| WO2004063337A2 (en) | 2003-01-07 | 2004-07-29 | Dyax Corporation | Kunitz domain library |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
| EP2015781A4 (en) * | 2005-09-12 | 2009-12-23 | Univ Johns Hopkins | COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| WO2008151088A2 (en) | 2007-06-01 | 2008-12-11 | University Of Maryland, Baltimore | Immunoglobulin constant region fc receptor binding agents |
| PE20090983A1 (es) * | 2007-11-09 | 2009-08-13 | Genentech Inc | Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina |
| US9051349B2 (en) | 2007-11-21 | 2015-06-09 | Alba Therapeutics Corporation | Larazotide acetate compositions |
| EP2451459B1 (en) * | 2009-07-07 | 2017-11-22 | Normoxys, Inc. | Method of reducing multi-drug resistance using inositol tripyrophosphate |
| WO2012079088A2 (en) | 2010-12-10 | 2012-06-14 | The Johns Hopkins University | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
| EP2788473A4 (en) | 2011-12-09 | 2015-11-11 | Univ Johns Hopkins | ARTIFICIAL ANTIGEN PRESENTING CELLS WITH DEFINED AND DYNAMIC FORM |
| DK3003343T3 (da) * | 2013-06-07 | 2020-02-03 | Univ Johns Hopkins | Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme |
-
2017
- 2017-10-04 KR KR1020197012909A patent/KR20190066040A/ko not_active Ceased
- 2017-10-04 EA EA201990868A patent/EA201990868A1/ru unknown
- 2017-10-04 JP JP2019517873A patent/JP2019535651A/ja active Pending
- 2017-10-04 AU AU2017339970A patent/AU2017339970A1/en not_active Abandoned
- 2017-10-04 WO PCT/US2017/055055 patent/WO2018067646A1/en not_active Ceased
- 2017-10-04 BR BR112019006735A patent/BR112019006735A2/pt not_active Application Discontinuation
- 2017-10-04 CN CN201780074408.5A patent/CN110177563A/zh active Pending
- 2017-10-04 MX MX2019003895A patent/MX2019003895A/es unknown
- 2017-10-04 CA CA3038809A patent/CA3038809A1/en not_active Abandoned
- 2017-10-04 EP EP17859077.4A patent/EP3522906B1/en active Active
- 2017-10-04 US US16/336,777 patent/US20190225670A1/en not_active Abandoned
- 2017-10-04 SG SG10202103032QA patent/SG10202103032QA/en unknown
-
2019
- 2019-03-28 IL IL265694A patent/IL265694A/en unknown
- 2019-04-12 ZA ZA2019/02344A patent/ZA201902344B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG10202103032QA (en) | 2021-05-28 |
| CA3038809A1 (en) | 2018-04-12 |
| JP2019535651A (ja) | 2019-12-12 |
| US20190225670A1 (en) | 2019-07-25 |
| MX2019003895A (es) | 2019-10-07 |
| AU2017339970A1 (en) | 2019-04-18 |
| KR20190066040A (ko) | 2019-06-12 |
| WO2018067646A1 (en) | 2018-04-12 |
| IL265694A (en) | 2019-05-30 |
| EP3522906A1 (en) | 2019-08-14 |
| EP3522906B1 (en) | 2022-03-23 |
| EA201990868A1 (ru) | 2019-09-30 |
| EP3522906A4 (en) | 2020-06-10 |
| CN110177563A (zh) | 2019-08-27 |
| ZA201902344B (en) | 2021-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019006735A2 (pt) | compostos e métodos para ativação da sinalização de tie2 | |
| BR112016028520A2 (pt) | métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina | |
| BR112017017286A2 (pt) | protease de cisteína | |
| BR112017017284A2 (pt) | protease de cisteína | |
| MX370689B (es) | Polipeptidos apelina. | |
| BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
| ECSP15042898A (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| BR112018003864A2 (pt) | método para preparação de uma composição de ácido hialurônico, composição, e, método para restauração de um tecido | |
| BR112018010052A2 (pt) | peptídeos com propriedades antiangiogênicas, antilinfangiogênicas e antiedêmicas e formulações de nanopartícula | |
| UA117096C2 (uk) | Поліпептид, що зв'язується з c5 комплементу людини | |
| MX2018002546A (es) | Composiciones que comprenden un compuesto de urolitina. | |
| BR112019008230A2 (pt) | compostos de polímero de liberação de sulfeto de hidrogênio | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| BR112018010160A2 (pt) | inibidor da c1 esterase humana recombinante e usos do mesmo | |
| MX2016011394A (es) | Moleculas de andamiaje a base de fibronectina estabilizada. | |
| BR112017008962A2 (pt) | proteínas de fusão inibidoras de c1 esterase e usos das mesmas | |
| PH12019501064A1 (en) | Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | |
| NZ744289A (en) | Composition containing amino acids | |
| NZ734845A (en) | Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease | |
| BR112019004270A2 (pt) | proteína livre de fenilalanina para o tratamento de pku | |
| BR112018009459A8 (pt) | formulação de selante e usos da mesma | |
| BR112018007686A2 (pt) | uso terapêutico de uma solução oftál¬mica aquosa es-teril | |
| EA202090654A1 (ru) | Композиция в качестве добавки кальция | |
| BR112018069489A2 (pt) | agente indutor da imunidade e métodos para preparar uma célula apresentadora de antígeno, para preparar uma célula t citotóxica e para induzir a imunidade | |
| BR112018011096A2 (pt) | novos peptídeos que têm atividade antimicrobiana e nova enzima capaz de converter resíduo de configuração l em aminoácido de configuração d em um peptídeo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |